Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Treatment satisfaction, adherence and behavioral assessment in patients de - escalating from natalizumab to interferon beta.
Selective inhibition of CCR7- TEM cells activation by a novel peptide targeting Kv1.3 in a rat EAE model.
HLA-DRα1 Constructs Block CD74 Expression and MIF Effects in Experimental Autoimmune Encephalomyelitis.
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis.
Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis.
Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.
Genmab announces positive top-line Phase II results of ofatumumab in multiple sclerosis
ALSUntangled No. 8: Low dose naltrexone for ALS.
Elevation of Sema4A Implicates Th Cell Skewing and the Efficacy of IFN-β Therapy in Multiple Sclerosis.
Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids.
Increased Serum Brain-derived Neurotrophic Factor in Multiple Sclerosis Patients on Interferon-β and Its Impact on Functional Abilities.
Thrombotic microangiopathy associated with interferon beta.
Santhera Announces Successful Outcome of Phase III Study with Catena®/Raxone® in Duchenne Muscular Dystrophy
Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis
Biogen Reports Another Tecfidera PML Case
Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion.
Nephrotic syndrome in multiple sclerosis patients who had undergone long-term interferon β-1b therapy.
Macrophage-specific chemokines induced via innate immunity by amino acid copolymers and their role in EAE.
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
Biogen Idec's long-acting beta interferon moves ahead in MS
Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in relapsing-Remitting Multiple Sclerosis
The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis.
Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells.
Rituximab for refractory digital infarcts and ulcers in systemic sclerosis.
Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication.

Pages